Valuation: Ovid Therapeutics Inc.

Market Cap 523M 456M 432M 392M 732M 50.2B 736M 5.14B 1.99B 25.46B 1.97B 1.92B 81.62B P/E 2026 *
-7.28x
P/E 2027 * -6.62x
Enterprise Value 523M 456M 432M 392M 732M 50.2B 736M 5.14B 1.99B 25.46B 1.97B 1.92B 81.62B EV / Sales 2026 *
639x
EV / Sales 2027 * 2,344x
Free-Float
93.28%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ovid Therapeutics Inc.

1 day+0.75%
Current month+1.12%
1 month-4.59%
3 months+14.41%
6 months+38.46%
Current year+65.64%
1 week 2.63
Extreme 2.63
2.8
1 month 2.61
Extreme 2.61
2.95
Current year 1.36
Extreme 1.36
3.1
1 year 1.12
Extreme 1.12
3.1
3 years 0.24
Extreme 0.2425
4.1
5 years 0.24
Extreme 0.2425
4.14
10 years 0.24
Extreme 0.2425
15.93
Manager TitleAgeSince
Chief Executive Officer 45 01/01/2026
Director of Finance/CFO 59 06/07/2026
Chief Tech/Sci/R&D Officer 60 02/12/2025
Director TitleAgeSince
Chairman 72 01/04/2014
Director/Board Member 81 23/11/2015
Director/Board Member 61 14/06/2017
Date Insider Type Main position Quantity % Market Cap. Importance
06/07/26 Free

Chief Financial Officer

50,000 0.0268%
06/07/26 Other

Chief Financial Officer

450,625 0.2414%
07/04/26 Free

Director

17,578 0.0133%
Change 5-day change 1-year change 3-year change Capi.($)
+0.75%0.00%+136.84%-31.99% 523M
+1.76%+3.62%+49.92%+101.12% 69.69B
+2.29%+0.32%+37.65%+77.03% 61.24B
+1.14%-3.74%-14.35%+365.92% 26.77B
+0.32%+2.58%+29.26%+14.12% 26.12B
+2.95%+0.54%-0.60%-12.74% 24.07B
+1.49%+5.15%+26.46%-15.89% 20.39B
-0.83%-11.15%+169.70%+295.44% 15.72B
+3.01%+0.27%+49.44%+168.18% 14.07B
+0.17%-4.07%-9.71%+484.05% 14.03B
Average +1.30%-1.14%+47.46%+144.52% 27.26B
Weighted average by Cap. +1.60%+0.20%+36.64%+128.69%

Financials

2026 *2027 *
Net sales 819K 714K 675K 613K 1.15M 78.57M 1.15M 8.04M 3.11M 39.85M 3.08M 3.01M 128M 223K 195K 184K 167K 312K 21.42M 314K 2.19M 847K 10.86M 839K 820K 34.82M
Net income -68.31M -59.52M -56.32M -51.14M -95.56M -6.55B -96.09M -671M -259M -3.32B -257M -251M -10.65B -84.77M -73.86M -69.9M -63.46M -119M -8.13B -119M -832M -322M -4.12B -318M -311M -13.22B
Net Debt - -
Logo Ovid Therapeutics Inc.
Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
Employees
23
Date Price Change Volume
17/09/26 $2.700 +0.75% 1,985,776
16/09/26 $2.680 -1.11% 1,428,324
15/09/26 $2.710 -1.09% 988,551
14/09/26 $2.740 +1.86% 1,199,520
11/09/26 $2.690 +2.28% 1,147,532
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2.700USD
Average target price
5.916USD
Spread / Average Target
+119.09%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OVID Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!